Navigation Links
CEL-SCI to Present at Rodman & Renshaw 9th Annual Healthcare Conference
Date:10/30/2007

VIENNA, Va., Oct. 30 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (Amex: CVM) announced that Geert Kersten, Chief Executive Officer, will be presenting at the Rodman & Renshaw 9th Annual Healthcare Conference being held at the New York Plaza Hotel from November 5-7, 2007. The presentation will be focused on its Phase III cancer product Multikine(R) which is the first biotech cancer product seeking to become a new first line standard of care treatment in cancer.

Mr. Kersten's presentation will be on Wednesday, November 7th, at 1:40 p.m. EDT. The presentation will be webcast live with slides and archived for 90 days after the conference. The webcast can be accessed at http://www.wsw.com/webcast/rrshq12/cvm or http://www.cel-sci.com.

About CEL-SCI's Phase III Cancer Drug Multikine:

In Phase II clinical trials Multikine was shown to be safe and well- tolerated, and to improve the patients' overall survival by 33% at a median of three and a half years following surgery. The U.S. Food and Drug Administration (FDA) gave the go-ahead for a Phase III clinical trial with Multikine in January 2007 and granted orphan drug status to Multikine in the neoadjuvant therapy of squamous cell carcinoma (cancer) of the head and neck in May 2007.

Multikine, a patented defined mixture of naturally derived cytokines, is the first immunotherapeutic agent in a new class of drugs called "Immune SIMULATORS." Immune SIMULATORS simulate the way our natural immune system acts in defending us against cancer. As opposed to other immunotherapies which are designed to target a single or limited number of specific
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. CEL-SCIS CEL-1000 Shown to Significantly Enhance Immune Response Against Avian Flu Antigen in Animals
2. CEL-SCI Presents Long-Term Cancer Survival Data With Multikine
3. CEL-SCIs Cel-1000 Shown to Significantly Enhance Immune Response Against Hepatitis B Antigen in Animals
4. The Past, Present and Future of HLA Typing
5. Sygnis Pharma AG announces date for presentation of clinical results
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
10. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
11. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... , June 18, 2013 Valeant Pharmaceuticals International, ... (the "Company") announced today that VPII Escrow Corp., a ... has launched its offer of approximately $3.2 billion aggregate ... Notes will be due in 2021 and in 2023, ... Company intends to use the net proceeds from the ...
(Date:6/18/2013)... June 18, 2013  Actavis, Inc. (NYSE: ACT ... with the U.S. Securities and Exchange Commission (SEC) a registration ... of Warner Chilcott plc (NASDAQ: WCRX ... Warner Chilcott (the "Form S-4"). As ... Chilcott have entered into a definitive agreement pursuant to ...
(Date:6/18/2013)... CITY, N.Y. , June 18, 2013 /PRNewswire/ ... that it has entered into an exclusive 25-year ... Mid-Atlantic regions with eWellness Corporation ("EWC") for its ... "An easy to use physical therapy program is ... diabetes and cardiovascular disease," said Chris Amandola ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 3Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 2Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 3Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 4Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 5Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 6Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 7Millennium HealthCare Signs Exclusive Distribution Agreement with eWellness Corporation for Northeast and Mid-Atlantic Regions 2Millennium HealthCare Signs Exclusive Distribution Agreement with eWellness Corporation for Northeast and Mid-Atlantic Regions 3
... , - Research Collaboration ... Jubilant Organosys Ltd, headquartered ... subsidiary,Jubilant Biosys Ltd, has signed a research,collaboration agreement ... into the international pharmaceutical company,s pre-clinical,pipeline. Under the ...
... EPSScentral LLC today announced its readiness to assist ... the face of WHO,s phase 5 classification of the ... 5 "... is a strong signal that a pandemic ... measures is short." (Logo: http://www.newscom.com/cgi-bin/prnh/20080701/DC26612LOGO ...
Cached Medicine Technology:Jubilant Enters Research Collaboration With AstraZeneca 2Jubilant Enters Research Collaboration With AstraZeneca 3Jubilant Enters Research Collaboration With AstraZeneca 4EPSScentral Responds to Pandemic Alert 2
(Date:6/19/2013)... Scott Tischler of Tischler Brothers Fitness unveils how to kick ... very first thing that should be done every morning is ... The body is dehydrated when it first wakes up and ... and will also kick start the metabolism first thing in ... the water to body temperature before it can be digested ...
(Date:6/19/2013)... According to Vanessa Grigoriadis, a contributing ... are creating new designer drugs featuring psychoactive effects by ... documents and patented formulas. She reported her findings to ... on June 4. , “Some of these drugs could ... on humans. Maybe some of them are tested on ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 As Mirena ... LLP highlights a recent news story from an NBC ... effects of the hormone-based contraceptive device. The Rottenstein Law ... to file Mirena lawsuits and who are ... The U.S. Food and Drug Administration has logged more ...
(Date:6/19/2013)... Sudden cardiac arrest can strike anyone, even a child, at ... minutes after cardiac arrest, but the average emergency medical service ... is highly probable if an automated external defibrillator or ... to this dire reality, US Representative Lois Capps (CA-24) has ... which would provide support for AED and CPR training programs ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 Transvaginal mesh lawsuits ... matter. A May 31 order addressed how to handle evidence ... preserve and test samples and device components removed from patients. ... informational website , complete with news about the device and ... are to obtain the samples from the medical facilities that ...
Breaking Medicine News(10 mins):Health News:Dangerous Designer Drugs Dodge Legal System 2Health News:Dangerous Designer Drugs Dodge Legal System 3Health News:Rottenstein Law Group LLP Comments on News Reports of Mirena IUD Side Effects 2Health News:AED.com Supports Automated External Defibrillator (AED) Legislation in Schools in US and UK 2Health News:Transvaginal Mesh Lawsuit News: NJ Mesh Consolidation Cases Moving Along, Rottenstein Law Group LLP Reports 2
... 11 MedImmune, the,global biologics unit of AstraZeneca, ... Holdings, Inc., announced today that they have entered,into ... commercialize,SBI Biotech,s anti-ILT7 protein for the potential treatment ... MedImmune has,global rights to any resulting product candidates ...
... back,to school, parents gain flexibility in what their ... Department of Agriculture (USDA),announced parents or legal guardians ... cow,s milk for children receiving National School Lunch ... growing diversity of,participants in the School Nutrition Programs ...
... Sept. 11 /Xinhua-PRNewswire-FirstCall/ -- Genesis,Pharmaceuticals Enterprises, Inc. (OTC ... pharmaceutical company in the People,s Republic,of China, today ... a,total value of approximately $12 million over the ... the 43rd Annual New Drugs Conference (the,"Conference") sponsored ...
... MIT study suggests , , THURSDAY, Sept. 11 (HealthDay News) -- ... your eyes. , A team of neuroscientists publishing ... they have tricked the brain into confusing one object the ... humans to learn to recognize objects. , People never really ...
... waiting room time more enjoyable and informative for patients, ... and helping doctors become more profitable in the process. ... is Ear, Nose & Throat Associates of South Florida ... month in Chicago at AOA-26 and OTO EXPO and ...
... NBTY, Inc. (NYSE:,NTY) (http://www.NBTY.com ), a leading global ... will web cast the,presentation by Harvey Kamil, President and ... Ideas Conference in New York on Wednesday,September 17, 2008., ... live on NBTY,s web site, (http://www.nbty.com ) on Wednesday, ...
Cached Medicine News:Health News:MedImmune Further Expands Autoimmune Disease Research Program Through Collaboration with SBI Biotech 2Health News:Parents Can Now Ask Schools to Serve Soymilk 2Health News:Genesis Pharmaceuticals Received New Purchase Orders Worth $12 Million 2Health News:Genesis Pharmaceuticals Received New Purchase Orders Worth $12 Million 3Health News:Time Teaches Brain to Recognize Objects 2Health News:Mediplay Makes Marketing More Profitable For Physicians 2Health News:Mediplay Makes Marketing More Profitable For Physicians 3Health News:NBTY to Web Cast Presentation at CL King Best Ideas Conference 2
Combination heat and moisture exchanger and bacterial/viral filters for Anesthesia and Respiratory applications....
Indications For Usage: ,Adult (recommended tidal volume >150ml), single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intended to ...
HME w/bacterial viral filter w/CO2...
Indications For Usage: ,Infant (recommended tidal volume 20-70ml), single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intended ...
Medicine Products: